Indication

Ventavis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominately patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

• About Ventavis

•      Indications

•      Clinical Trials

•      Efficacy

•           Clinical Improvement

•           Improved Exercise
            Capacity

•           Functional Class
            Improvement

•           Improved
            Hemodynamics

•      Safety Profile

•      Dosage & Administration

•      FAQs

• About the I-neb AAD
  System

• Services for Your Patients

• Resources

• Prescribing Information

• For Patients and
  Caregivers

Ventavis^® (iloprost) Support

Comprehensive Services and Support

• Patient enrollment and referrals to specialty pharmacy distributors
• Verification of insurance and/or patient assistance programs
• Training in use of the I-neb AAD System by nurse educators
• Patient support from registered nurses by phone
• Patient education and support by e-mail and newsletter

Request a Ventavis representative

1) Use the form below to submit your contact information to Actelion Pharmaceuticals US, Inc. and a representative will contact you by phone or e-mail to arrange an appointment.

			Required fields are in red.
	Name
	Specialty
	Address 1
	Address 2
	City
	State		Zip
	Phone
	E-mail

2) If you would like to contact your local Ventavis representative directly, please fill in your name, zip code, and e-mail address below and we will send you his or her contact information.

Unsubscribe

To unsubscribe from Ventavis communications click here.

IMPORTANT SAFETY INFORMATION

Hypotension leading to syncope has been observed; Ventavis should therefore not be initiated in patients with systolic blood pressure less than 85 mmHG. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension. Ventavis inhalation may cause brochospasm and patients with a history of hyperreactive airway disease may be more sensitive. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Ventavis has the potential to increase risk of bleeding, particularly in patients maintained on anticoagulants.

Please see full Prescribing Information